CA2464316A1 - Therapeutic light-emitting device - Google Patents
Therapeutic light-emitting device Download PDFInfo
- Publication number
- CA2464316A1 CA2464316A1 CA002464316A CA2464316A CA2464316A1 CA 2464316 A1 CA2464316 A1 CA 2464316A1 CA 002464316 A CA002464316 A CA 002464316A CA 2464316 A CA2464316 A CA 2464316A CA 2464316 A1 CA2464316 A1 CA 2464316A1
- Authority
- CA
- Canada
- Prior art keywords
- light
- ambulatory device
- ambulatory
- emitting semiconductor
- organic light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0653—Organic light emitting diodes
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/11—OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/10—Organic polymers or oligomers
- H10K85/111—Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
- H10K85/114—Poly-phenylenevinylene; Derivatives thereof
Abstract
An ambulatory device for use in a therapeutic and/or cosmetic treatment, the device comprises an organic light-emitting semiconductor which, in use, cove rs an area to be treated and emits electromagnetic radiation to cause said therapeutic and/or cosmetic treatment of the area. The light source may be extensive to provide uniform irradiation of the area to be treated and may b e pulsed. The device may also include a photopharmaceutical.
Description
Title: Therapeutic Light-Emitting Device Field of the Invention The invention relates to a device for use in therapeutic and/or cosmetic treatment, particularly a treatment which involves exposure of part of the body to electromagnetic radiation. The invention also relates to such a device and a photo therapeutic agent for use therewith.
Background to the Invention Light can be used to treat a wide variety of diseases. When light alone is used to treat a disease, the treatment is referred to as phototherapy. Light may be used in conjunction with a pharmaceutical in which case the treatment is called photodynamic therapy (PDT).
These therapies can be used to treat a variety of skin and internal diseases.
In PDT, a light-sensitive therapeutic agent known as a photopharmaceutical is supplied externally or internally to an area of the body which is to be treated. That area is then exposed to light of a suitable frequency and intensity to activate the photopharmaceutical. A
variety of photopharmaceutical agents are currently available. For example there are topical agents such as 5-aminolevulinic acid hydrochloride (Crawford Pharmaceuticals), methylaminolevulinic acid (Metfix~, Photocure). There are also injectable drugs used primarily for internal malignancies, including Photofin~ (from Axcan) and Foscan~ (from Biolitech Ltd). Often, the drug is applied in a non-active form that is metabolised to a light-sensitive photopharmaceutical.
In photodynamic therapy, the primary technique for supplying light to the photopharmaceutical is to project light of a suitable wavelength from standalone light sources such as lasers or filtered arc lamps. These sources are cumbersome and expensive, and are therefore only suitable for use in hospitals. This leads to inconvenience for the patient, and high cost for the treatment. High light irradiances are needed in order to treat an acceptable number of patients per day (for the treatment to be cost effective) and to avoid unduly inconveniencing the patient.
WO 98/46130 (Chen and Wiscombe) discloses arrays of LEDs for use in photodynamic therapy. The small LED sources taught therein result in uneven light incident on the patient. Fabrication of arrays is complicated because of the large number of connections required. The devices shown therein are designed for hospital treatment GB 2360461 (Whitehirst) discloses a flexible garment which uses a conventional photodynamic therapy light source to produce light which is then transmitted through optical fibres. As such light sources are heavy, the device is not ambulatory and is limited to hospital use.
US 5698866 (Doiron et al) discloses a light source using over-driven inorganic LEDs.
The resulting light output is not even. A heat-sinking mechanism is required, and the device is suitable only for hospital treatment.
WO 93/21842 (Bower et al) disclose light sources using inorganic LEDs.
Although transportable, the device is not suitable for ambulatory use by a patient at home and clinical treatment is envisaged.
A further problem with existing approaches is that it can be difficult to achieve uniform illumination with such sources, especially on curved body parts.
summary of the Invention According to a first aspect of the present invention there is provided an ambulatory device for use in a therapeutic and/or cosmetic treatment, the device comprising an organic light-emitting semiconductor which, in use, covers an area to be treated and emits electromagnetic radiation to cause said treatment of the area.
Preferably, the device is for use in the treatment of a human or animal patient by photodynamic therapy.
Preferably, the organic semiconductor is operable to emit light in the wavelength range of 300-900 nm.
Organic semiconductors are lightweight, and can readily be powered by portable low voltage power supplies, such as batteries, forming a totally self contained portable unit.
Indeed, the photo-therapeutic device may to advantage include a power supply for operating the organic light-emitting semiconductor. The device is sufficiently portable to enable ambulatory treatment i.e. treatment in which the patient can move around freely. It can be subsequently removed in the patient's own time, so that treatment could take place at home or at work. This gives greater convenience and lower cost (from avoiding either an out-patient or in-patient stay in hospital). It also means that lower light levels can be used since exposure can occur for a longer period of time. This overcomes a problem of pain induced in some patients by the high irradiances from conventional sources used in hospitals. In addition lower irradiance is more effective in PDT due to reduction of the extent of photobleaching of the photopharmaceutical.
Preferably, the light emitting semiconductor provides an extensive light emitting area. In contrast to point sources (such as inorganic light emitting diodes) a more even light output is thereby produced. The light emitting semiconductor preferably has an extent of at least lcm2 and preferably is in the range 3cm2 (for small lesions) through to 100cm2 although semiconductors as large as 400cmz might be used for a head. Preferably also, the light emitting surface of the semiconductor is continuous. The light emitting surface may conveniently be square, e.g. lcm x lcm, 2cm x 2cm, Scm x Scm, lOcm x lOcm, or circular.
Background to the Invention Light can be used to treat a wide variety of diseases. When light alone is used to treat a disease, the treatment is referred to as phototherapy. Light may be used in conjunction with a pharmaceutical in which case the treatment is called photodynamic therapy (PDT).
These therapies can be used to treat a variety of skin and internal diseases.
In PDT, a light-sensitive therapeutic agent known as a photopharmaceutical is supplied externally or internally to an area of the body which is to be treated. That area is then exposed to light of a suitable frequency and intensity to activate the photopharmaceutical. A
variety of photopharmaceutical agents are currently available. For example there are topical agents such as 5-aminolevulinic acid hydrochloride (Crawford Pharmaceuticals), methylaminolevulinic acid (Metfix~, Photocure). There are also injectable drugs used primarily for internal malignancies, including Photofin~ (from Axcan) and Foscan~ (from Biolitech Ltd). Often, the drug is applied in a non-active form that is metabolised to a light-sensitive photopharmaceutical.
In photodynamic therapy, the primary technique for supplying light to the photopharmaceutical is to project light of a suitable wavelength from standalone light sources such as lasers or filtered arc lamps. These sources are cumbersome and expensive, and are therefore only suitable for use in hospitals. This leads to inconvenience for the patient, and high cost for the treatment. High light irradiances are needed in order to treat an acceptable number of patients per day (for the treatment to be cost effective) and to avoid unduly inconveniencing the patient.
WO 98/46130 (Chen and Wiscombe) discloses arrays of LEDs for use in photodynamic therapy. The small LED sources taught therein result in uneven light incident on the patient. Fabrication of arrays is complicated because of the large number of connections required. The devices shown therein are designed for hospital treatment GB 2360461 (Whitehirst) discloses a flexible garment which uses a conventional photodynamic therapy light source to produce light which is then transmitted through optical fibres. As such light sources are heavy, the device is not ambulatory and is limited to hospital use.
US 5698866 (Doiron et al) discloses a light source using over-driven inorganic LEDs.
The resulting light output is not even. A heat-sinking mechanism is required, and the device is suitable only for hospital treatment.
WO 93/21842 (Bower et al) disclose light sources using inorganic LEDs.
Although transportable, the device is not suitable for ambulatory use by a patient at home and clinical treatment is envisaged.
A further problem with existing approaches is that it can be difficult to achieve uniform illumination with such sources, especially on curved body parts.
summary of the Invention According to a first aspect of the present invention there is provided an ambulatory device for use in a therapeutic and/or cosmetic treatment, the device comprising an organic light-emitting semiconductor which, in use, covers an area to be treated and emits electromagnetic radiation to cause said treatment of the area.
Preferably, the device is for use in the treatment of a human or animal patient by photodynamic therapy.
Preferably, the organic semiconductor is operable to emit light in the wavelength range of 300-900 nm.
Organic semiconductors are lightweight, and can readily be powered by portable low voltage power supplies, such as batteries, forming a totally self contained portable unit.
Indeed, the photo-therapeutic device may to advantage include a power supply for operating the organic light-emitting semiconductor. The device is sufficiently portable to enable ambulatory treatment i.e. treatment in which the patient can move around freely. It can be subsequently removed in the patient's own time, so that treatment could take place at home or at work. This gives greater convenience and lower cost (from avoiding either an out-patient or in-patient stay in hospital). It also means that lower light levels can be used since exposure can occur for a longer period of time. This overcomes a problem of pain induced in some patients by the high irradiances from conventional sources used in hospitals. In addition lower irradiance is more effective in PDT due to reduction of the extent of photobleaching of the photopharmaceutical.
Preferably, the light emitting semiconductor provides an extensive light emitting area. In contrast to point sources (such as inorganic light emitting diodes) a more even light output is thereby produced. The light emitting semiconductor preferably has an extent of at least lcm2 and preferably is in the range 3cm2 (for small lesions) through to 100cm2 although semiconductors as large as 400cmz might be used for a head. Preferably also, the light emitting surface of the semiconductor is continuous. The light emitting surface may conveniently be square, e.g. lcm x lcm, 2cm x 2cm, Scm x Scm, lOcm x lOcm, or circular.
The device may be planar, or may be curved in advance or in situ to conform to the surface of the area to be exposed to light from the organic light-emitting semiconductor.
Preferably, the device is flexible so as to be capable of being formed into any of a number of possible different configurations in advance or extemporaneously to the shape of the body part to which it is to be applied. The device may be disposable, i.e.
used to deliver one treatment and then thrown away.
The device may be used as a stmt, for example a tube of 1.25 - 2.25cm radius of say 10-l2cm length for use inside the oesophagus.
Preferably, the device includes a transparent or translucent substrate layer of preferably even thickness which additionally functions as a support layer for the organic light-emitting semiconductor. The support layer can also act as a barrier layer and be selected to prevent oxygen and/or moisture from penetrating the organic light-emitting semiconductor and is preferably glass. A glass/plastic laminate structure may also be used and there may be a further barrier layer overlying the organic light-emitting semiconductor.
The device conveniently includes an adhesive surface for attaching the device to a patient For planar devices, the preferred substrate is glass. However, as organic semiconductors can be flexible, flexible devices can be made using a combination of flexible components (including the substrate). Indium tin oxide (ITO) coated polyester is a suitable substrate though its inferior barrier properties mean that devices using this substrate require storage (or packaging) in an inert atmosphere. Another substrate that can be used is a laminate of alternate layers of plastic and a suitable glass. Such laminates or indeed a single glass layer if sufficiently thin, can display a suitable elastic quality to be useable in a flexible device.
Preferably, the organic light-emitting semiconductor is an organic light-emitting diode.
Preferably the light-emitting diode comprises a layer of the conducting polymer PEDOT/PSS which assists with hole injection into the light-emitting layer, reducing the operating voltage of the device. The light-emitting diode, may comprise an organic light-emitting layer of OC,C,o PPV (see figure 2) which can readily be made into films by spin-coating and gives orange-red light emission. The light-emitting semiconductor may be based on small organic molecules, light-emitting polymers, light-emitting dendrimers or other organic light-emitting semiconductor materials.
A multilayer organic semiconductor structure is only one option and a single organic semiconductor layer can fulfill the required functions, namely that electrons and holes are injected at opposite contacts, transported in the layer where capture of opposite charges then forms an excited state which can then emit light. A single semiconducting layer device can be used with a further layer of the conducting polymer PEDOT on an indium tin oxide layer.
The devices may be provided with a photochemical and/or a photopharmaceutical preparation present. This may be in the form of a gel, ointment or cream.
Alternatively, or as well, the device may be provided with a thin film impregnated with the photopharmaceutical. Typically, the photopharmaceutical preparation is provided as a layer in contact with the light source. Provided that the photopharmaceutical preparation is transparent or sufficiently translucent for the frequency of stimulating light, the resulting device can be readily applied without a separate step of applying the photopharmaceutical to a patient. Creams which would scatter the light may nevertheless be used if they are absorbed before the light source is switched on. A photopharmaceutical layer may be covered by a peelable release medium, such as a silicone-backed sheet. The photopharmaceutical preparation may comprise an inactive compound which is metabolised in vivo to an active compound. Delivery of the photopharmaceutical can be assisted by iontophoresis.
The output of light from the organic light-emitting semiconductor may be pulsed and an electronic control circuit or microprocessor may be provided to control this pulsing and/or other aspects of device function such as duration of exposures) of the area to be treated and the intensity of emitted light. Pulsed devices may be provided with a preparation of a photochemical and/or a photopharmaceutical substance which is photobleachable or which is metabolised in vivo to a photobleachable chemical species The output of the semiconductor may take the form of a train of pulses, preferably in which the duration of the pulses is substantially the same as the interval between successive pulses. The period of the pulse train may, for example, be in the range of 20ms to 2000s, depending on the photobleaching characteristics of said substance.
According to a second aspect of the present invention there is provided an ambulatory device for use in therapeutic treatment (preferably by photodynamic therapy), the device comprising a light-emitting layer, wherein the device including said layer is flexible so that, when applied to a curved part of a body, the light-emitting layer conforms to the shape of the surface of the area to be treated.
Preferably, the device includes attachment means comprising an adhesive surface to enable the device to be attached to a patient.
Further preferred features correspond to the first aspect above.
According to a third aspect of the present invention there is provided an ambulatory device according to the first or second aspect above and a photo-therapeutic chemical, preferably a photopharmaceutical agent for use in photodynamic therapy, for use with the device.
The pulsing of the light used to activate a phototherapeutic chemical can also be advantageous in rigid devices or, devices having types of light source, for example a laser, other than organic semi conductors.
Thus, according to a further aspect of the invention, there is provided an ambulatory device for use in photodynamic therapy, the device comprising an electromagnetic radiation source, attachment means for attaching the electromagnetic radiation source to a patient and control means for activating and deactivating the source to cause the latter to emit a train of light pulses for activating a photodynamic chemical, whilst reducing the effects of photo bleaching on the chemical.
Preferably, the ambulatory device is provided with a photochemical and/or a photopharmaceutical preparation present. Preferred features of the preparation and its delivery are as above. In particular, the photochemical and/or photopharmaceutical may be photobleachable or may be metabolised in vivo to a photobleachable chemical species.
The means for activating and deactivating the source may control other aspects of device function such as duration of exposures) of the area to be treated and the intensity of emitted light.
The control means may to advantage be operable to cover the source to emit a pulse train having any one or more of the preferred features of the pulse train produced by a device in accordance with the first aspect of the invention.
Brief Description of the Drawings An embodiment of the present invention will now be described, by way of example only, with reference to the following figures in which:
Figure 1 is a schematic cross-section through a therapeutic device according to the present invention;
Figure 2 is the chemical structure of the polymer OC,C,o PPV used in the device;
and Figure 3 is a graph of the spectrum of light emitted by a therapeutic device including OC,C,o-PPV as the light emitting layer;
Figures 4(a) through 4(d) are graphs of the current voltage characteristics, the light output-voltage characteristics; the light output-current density characteristics and the external quantum efficiency-voltage characteristics respectively of the device of Figure 3;
Figure 5 is a graph of the spectrum of light emitted by a device in which the light-emitting layer is poly(dihexyfluorene);
Figure 6 is a cicuit-diagram of a 108 gram power source for use with the invention;
and Figures 7(a) through (c) illustrate the light output from OC,C,o PPV devices operated with pulses of period (a) 20ms, (b) 200ms, (c) 2000ms.
Detailed Descr~tion A photo-therapeutic device shown generally as 1 is connected to by way of leads 3 to a battery power supply 2. The photo-therapeutic device comprises a light-generating element shown generally as 10 which is powered by the power supply 2 The light generating element 10 comprises an organic light-emitting diode using a layer of the polymer OC,C,o PPV as the light-emitting layer 14 in between suitable contacts. The hole injecting contact consists of an indium tin oxide coated glass substrate (11 and 12) coated with a layer 13 of the conducting polymer poly(3,4-ethylenedioxyhiophene) doped with polystyrenesulphonate (PEDOT/PSS). The electron injecting contact is a layer of calcium 15 which is chosen because of its low work function and is capped with aluminium 16. Light emission occurs when a current is passed between the contacts.
The lower electrode layer 12 and the glass substrate 11 are transparent. Glass is a suitable material as it also has the properties of being transparent and both oxygen and water-proof.
An upper support layer 18, also formed from glass, acts as a barrier to water and oxygen, provides additional mechanical support and is attached to the upper electrode layer 16 and is sealed by means of an epoxy layer 17. Adhesive tape 19 extends over the light-generating element 10 and beyond the element 10 to provide adhesive surfaces 22 and 24 for attaching the device to a patient. Prior to attachment, these surfaces are protected by removable plastics films 20 and 21.
Figure 2 illustrates the chemical structure of OC,C,o PPV. The main features are a conjugated backbone enabling charge transport, and giving an energy gap in the visible region of the spectrum. The alkoxy substituents confer solubility, and thin films of the polymer can readily be prepared by spin-coating.
Light is passed to the patient's skin from the light-generating element 10 through the transparent substrate 11. In a first example, the transparent lower support layer 11 and upper support layer 18 are planar and rigid, giving mechanical strength.
Batteries are a suitable power supply with control electronics incorporating controls for time of exposure, including the possibility of a delayed start to allow a photopharmaceutical to be metabolised into its photoactive form. Controls for brightness and pulsing may be included.
An example of a method of making the device will now be described. The indium tin oxide coated glass substrate 11 and 12 (Merck 20SZ/~) was cleaned by ultrasound in acetone followed by propan-2-of (10 minutes of each). After drying, and an optional step of exposure to an oxygen plasma, a layer of the conducting polymer PEDOT/PSS
(Bayer Baytron VP A14083) was spin-coated from aqueous solution at a spin speed of 2200 rpm for 1 minute. The film was baked at 80°C for 3 minutes. The light-emitting polymer OC,C,o PPV (see figure 2) was then deposited by spin-coating a solution of S
mg/ml of the polymer in chlorobenzene at a speed of 1750 rpm. The resulting film was in the region of 100nm thick. This and subsequent fabrication steps were carried out in the inert atmosphere of a nitrogen glove box. The structure was loaded into an evaporator (Edwards 306) to allow the deposition of the top contact. A thin layer of calcium (25nm) was evaporated thermally, followed by a thicker layer ( 140nm) of aluminium.
The pressure during the evaporations was 1.5-SxIO~ mbar, and the two metals were deposited without breaking the vacuum. The above layers were then encapsulated by a glass layer 18 attached with epoxy resin 7. Adhesive tape 19 was applied and covered by a plastics films 20 and 21.
In order to test the device it was connected to a power supply (Keithley 2400 source measure unit). The light-emitting area was 1 cm2. When a voltage (in the range 3-10 V) was applied, orange light emission through the substrate was observed. The device generated an irradiance in the range 0-IOmW/cm2 which is considerably lower than those generated by conventional sources, such as lasers and filtered lamps, as these typically generate irradiances in the region 75-150mW/cmz~ Alternatively the device could be driven by applying a current, and the intensity of the light was approximately proportional to the current supplied. The spectrum of the light emitted is shown in Figure 3. The device is applied to skin by removing the plastic films 20 and 21 and allowing the adhesive tape to stick to the skin.
The current-voltage, light output-voltage, light output-current density characteristics and the external quantum efficiency (EQE)-voltage characteristics are shown in the form of graphs in Figures 4(a) through 4(d).
A similar device was made using poly (dihexylfluorene) as the light-emitting layers, giving emission in the blue-green region of the spectrum, as shown in the graph of Figure 5 The lcm x lcm device weighed 1.26g and was used with a 108g battery power source, providing a light-weight ambulatory device. The power source consists of 4 conventional AA batteries and the simple current regulating circuit of Figure 6. The 108g power source also provides suitable power output for a 2cm x 2cm device. A 200g battery pack can power a Scm x Scm device.
The device could be used for skin and internal disorders. A range of pre-malignant, malignant and inflammatory diseases would be the target. Examples of pre-malignant skin disease are Bowen's disease, solar keratosis, arsenical keratosis, Paget's disease and radiodermatitis. Malignant diseases include all types of basal cell carcinomas, squamous cell carcinomas, secondary metastases, cutaneous T-cell lymphomas.
Inflammatory skin diseases include all types of dermatitis and psoriasis.
Further diseases that are potential targets are a range of pre-malignant, malignant and non-cutaneous disorders such as primary and metastatic tumours, as well as inflammatory disorders, eg connective tissue disease, all types of arthritis, inflammatory bowel disease.
Photopharmaceuticals can undergo reversible light-induced change, especially at high irradiances, which reduces the effectiveness of subsequent treatment - an effect referred to as photobleaching.
As reversible photobleaching of the photopharmaceutical is known to result in reduced penetration of light into the target tissue, a modified version of this device has a facility automatically to switch on and off the irradiation so delivering the desired dose, limiting photobleaching and enabling fresh uptake/metabolism of the photopharmaceutical within remaining viable target cells. This would have the clear benefit of increasing therapeutic effectiveness. The pulse trains constituting the light-output of such pulsed devices (periods 20, 200, 2000ms) are shown in Figure 7. Pulsed operation with a period of 20s, 200s and 2000s was also demonstrated and longer periods can be envisaged. Pulse shape and duration can readily be optimised for a particular application by experiment and calculation. In the examples shown, each period is constituted be a pulse and an interval between it and the next pulse, the interval being the same as the duration of the pulse.
The light-emitting device would be used either on its own as a simple light source applied to the skin or via an internal appliance such as a nasogastric tube, chest drain or stmt. For skin lesion management, the device would be used either alone or in combination with the photopharmaceutical in a translucent base such as a gel or ointment applied as a single dressing. Creams which scatter light may be used if they are sufficiently absorbed into the skin. A range of photopharmaceutical agents are currently available and it is expected that new agents of greater specificity and phototoxic effect will emerge. Examples of topical agents presently used include 5-aminolevulinic acid hydrochloride (Crawford Pharmaceuticals), methylaminolevulinc acid (Metfix, Photocure). Injectable drugs used in the main for internal malignancies, are two in number, Photofrin (Axcan) and Foscan (Biolitech).
A second example of the invention consists of a flexible device. Here the substrate consists of a polyester film in place of glass layer 11. Layers 12 to 16 are as for the first example. Epoxy layer 17 is very thin, and layer 18 is polyester. The inferior barrier properties of the plastic layers 11 and 18 mean that this device must be stored (or packaged) in an inert atmosphere such as dry nitrogen, but can be operated in air.
In this example, the element 10 is able to flex to fit the shape of a part of the patient's body, such as the arm. In this example, the transparent support layer and upper support layer are made from a thin flexible glass, a plastic/glass laminate or indium tin (ITO) coated polyester. The latter would be stored in an inert atmosphere until it is used.
Further alterations and amendments can be made by one skilled in the art within the scope of the invention herein disclosed. For example, the invention could be used, with a photopharmaceutical, in a cosmetic treatment, and/or have veterinary, as well as medical, applications.
Preferably, the device is flexible so as to be capable of being formed into any of a number of possible different configurations in advance or extemporaneously to the shape of the body part to which it is to be applied. The device may be disposable, i.e.
used to deliver one treatment and then thrown away.
The device may be used as a stmt, for example a tube of 1.25 - 2.25cm radius of say 10-l2cm length for use inside the oesophagus.
Preferably, the device includes a transparent or translucent substrate layer of preferably even thickness which additionally functions as a support layer for the organic light-emitting semiconductor. The support layer can also act as a barrier layer and be selected to prevent oxygen and/or moisture from penetrating the organic light-emitting semiconductor and is preferably glass. A glass/plastic laminate structure may also be used and there may be a further barrier layer overlying the organic light-emitting semiconductor.
The device conveniently includes an adhesive surface for attaching the device to a patient For planar devices, the preferred substrate is glass. However, as organic semiconductors can be flexible, flexible devices can be made using a combination of flexible components (including the substrate). Indium tin oxide (ITO) coated polyester is a suitable substrate though its inferior barrier properties mean that devices using this substrate require storage (or packaging) in an inert atmosphere. Another substrate that can be used is a laminate of alternate layers of plastic and a suitable glass. Such laminates or indeed a single glass layer if sufficiently thin, can display a suitable elastic quality to be useable in a flexible device.
Preferably, the organic light-emitting semiconductor is an organic light-emitting diode.
Preferably the light-emitting diode comprises a layer of the conducting polymer PEDOT/PSS which assists with hole injection into the light-emitting layer, reducing the operating voltage of the device. The light-emitting diode, may comprise an organic light-emitting layer of OC,C,o PPV (see figure 2) which can readily be made into films by spin-coating and gives orange-red light emission. The light-emitting semiconductor may be based on small organic molecules, light-emitting polymers, light-emitting dendrimers or other organic light-emitting semiconductor materials.
A multilayer organic semiconductor structure is only one option and a single organic semiconductor layer can fulfill the required functions, namely that electrons and holes are injected at opposite contacts, transported in the layer where capture of opposite charges then forms an excited state which can then emit light. A single semiconducting layer device can be used with a further layer of the conducting polymer PEDOT on an indium tin oxide layer.
The devices may be provided with a photochemical and/or a photopharmaceutical preparation present. This may be in the form of a gel, ointment or cream.
Alternatively, or as well, the device may be provided with a thin film impregnated with the photopharmaceutical. Typically, the photopharmaceutical preparation is provided as a layer in contact with the light source. Provided that the photopharmaceutical preparation is transparent or sufficiently translucent for the frequency of stimulating light, the resulting device can be readily applied without a separate step of applying the photopharmaceutical to a patient. Creams which would scatter the light may nevertheless be used if they are absorbed before the light source is switched on. A photopharmaceutical layer may be covered by a peelable release medium, such as a silicone-backed sheet. The photopharmaceutical preparation may comprise an inactive compound which is metabolised in vivo to an active compound. Delivery of the photopharmaceutical can be assisted by iontophoresis.
The output of light from the organic light-emitting semiconductor may be pulsed and an electronic control circuit or microprocessor may be provided to control this pulsing and/or other aspects of device function such as duration of exposures) of the area to be treated and the intensity of emitted light. Pulsed devices may be provided with a preparation of a photochemical and/or a photopharmaceutical substance which is photobleachable or which is metabolised in vivo to a photobleachable chemical species The output of the semiconductor may take the form of a train of pulses, preferably in which the duration of the pulses is substantially the same as the interval between successive pulses. The period of the pulse train may, for example, be in the range of 20ms to 2000s, depending on the photobleaching characteristics of said substance.
According to a second aspect of the present invention there is provided an ambulatory device for use in therapeutic treatment (preferably by photodynamic therapy), the device comprising a light-emitting layer, wherein the device including said layer is flexible so that, when applied to a curved part of a body, the light-emitting layer conforms to the shape of the surface of the area to be treated.
Preferably, the device includes attachment means comprising an adhesive surface to enable the device to be attached to a patient.
Further preferred features correspond to the first aspect above.
According to a third aspect of the present invention there is provided an ambulatory device according to the first or second aspect above and a photo-therapeutic chemical, preferably a photopharmaceutical agent for use in photodynamic therapy, for use with the device.
The pulsing of the light used to activate a phototherapeutic chemical can also be advantageous in rigid devices or, devices having types of light source, for example a laser, other than organic semi conductors.
Thus, according to a further aspect of the invention, there is provided an ambulatory device for use in photodynamic therapy, the device comprising an electromagnetic radiation source, attachment means for attaching the electromagnetic radiation source to a patient and control means for activating and deactivating the source to cause the latter to emit a train of light pulses for activating a photodynamic chemical, whilst reducing the effects of photo bleaching on the chemical.
Preferably, the ambulatory device is provided with a photochemical and/or a photopharmaceutical preparation present. Preferred features of the preparation and its delivery are as above. In particular, the photochemical and/or photopharmaceutical may be photobleachable or may be metabolised in vivo to a photobleachable chemical species.
The means for activating and deactivating the source may control other aspects of device function such as duration of exposures) of the area to be treated and the intensity of emitted light.
The control means may to advantage be operable to cover the source to emit a pulse train having any one or more of the preferred features of the pulse train produced by a device in accordance with the first aspect of the invention.
Brief Description of the Drawings An embodiment of the present invention will now be described, by way of example only, with reference to the following figures in which:
Figure 1 is a schematic cross-section through a therapeutic device according to the present invention;
Figure 2 is the chemical structure of the polymer OC,C,o PPV used in the device;
and Figure 3 is a graph of the spectrum of light emitted by a therapeutic device including OC,C,o-PPV as the light emitting layer;
Figures 4(a) through 4(d) are graphs of the current voltage characteristics, the light output-voltage characteristics; the light output-current density characteristics and the external quantum efficiency-voltage characteristics respectively of the device of Figure 3;
Figure 5 is a graph of the spectrum of light emitted by a device in which the light-emitting layer is poly(dihexyfluorene);
Figure 6 is a cicuit-diagram of a 108 gram power source for use with the invention;
and Figures 7(a) through (c) illustrate the light output from OC,C,o PPV devices operated with pulses of period (a) 20ms, (b) 200ms, (c) 2000ms.
Detailed Descr~tion A photo-therapeutic device shown generally as 1 is connected to by way of leads 3 to a battery power supply 2. The photo-therapeutic device comprises a light-generating element shown generally as 10 which is powered by the power supply 2 The light generating element 10 comprises an organic light-emitting diode using a layer of the polymer OC,C,o PPV as the light-emitting layer 14 in between suitable contacts. The hole injecting contact consists of an indium tin oxide coated glass substrate (11 and 12) coated with a layer 13 of the conducting polymer poly(3,4-ethylenedioxyhiophene) doped with polystyrenesulphonate (PEDOT/PSS). The electron injecting contact is a layer of calcium 15 which is chosen because of its low work function and is capped with aluminium 16. Light emission occurs when a current is passed between the contacts.
The lower electrode layer 12 and the glass substrate 11 are transparent. Glass is a suitable material as it also has the properties of being transparent and both oxygen and water-proof.
An upper support layer 18, also formed from glass, acts as a barrier to water and oxygen, provides additional mechanical support and is attached to the upper electrode layer 16 and is sealed by means of an epoxy layer 17. Adhesive tape 19 extends over the light-generating element 10 and beyond the element 10 to provide adhesive surfaces 22 and 24 for attaching the device to a patient. Prior to attachment, these surfaces are protected by removable plastics films 20 and 21.
Figure 2 illustrates the chemical structure of OC,C,o PPV. The main features are a conjugated backbone enabling charge transport, and giving an energy gap in the visible region of the spectrum. The alkoxy substituents confer solubility, and thin films of the polymer can readily be prepared by spin-coating.
Light is passed to the patient's skin from the light-generating element 10 through the transparent substrate 11. In a first example, the transparent lower support layer 11 and upper support layer 18 are planar and rigid, giving mechanical strength.
Batteries are a suitable power supply with control electronics incorporating controls for time of exposure, including the possibility of a delayed start to allow a photopharmaceutical to be metabolised into its photoactive form. Controls for brightness and pulsing may be included.
An example of a method of making the device will now be described. The indium tin oxide coated glass substrate 11 and 12 (Merck 20SZ/~) was cleaned by ultrasound in acetone followed by propan-2-of (10 minutes of each). After drying, and an optional step of exposure to an oxygen plasma, a layer of the conducting polymer PEDOT/PSS
(Bayer Baytron VP A14083) was spin-coated from aqueous solution at a spin speed of 2200 rpm for 1 minute. The film was baked at 80°C for 3 minutes. The light-emitting polymer OC,C,o PPV (see figure 2) was then deposited by spin-coating a solution of S
mg/ml of the polymer in chlorobenzene at a speed of 1750 rpm. The resulting film was in the region of 100nm thick. This and subsequent fabrication steps were carried out in the inert atmosphere of a nitrogen glove box. The structure was loaded into an evaporator (Edwards 306) to allow the deposition of the top contact. A thin layer of calcium (25nm) was evaporated thermally, followed by a thicker layer ( 140nm) of aluminium.
The pressure during the evaporations was 1.5-SxIO~ mbar, and the two metals were deposited without breaking the vacuum. The above layers were then encapsulated by a glass layer 18 attached with epoxy resin 7. Adhesive tape 19 was applied and covered by a plastics films 20 and 21.
In order to test the device it was connected to a power supply (Keithley 2400 source measure unit). The light-emitting area was 1 cm2. When a voltage (in the range 3-10 V) was applied, orange light emission through the substrate was observed. The device generated an irradiance in the range 0-IOmW/cm2 which is considerably lower than those generated by conventional sources, such as lasers and filtered lamps, as these typically generate irradiances in the region 75-150mW/cmz~ Alternatively the device could be driven by applying a current, and the intensity of the light was approximately proportional to the current supplied. The spectrum of the light emitted is shown in Figure 3. The device is applied to skin by removing the plastic films 20 and 21 and allowing the adhesive tape to stick to the skin.
The current-voltage, light output-voltage, light output-current density characteristics and the external quantum efficiency (EQE)-voltage characteristics are shown in the form of graphs in Figures 4(a) through 4(d).
A similar device was made using poly (dihexylfluorene) as the light-emitting layers, giving emission in the blue-green region of the spectrum, as shown in the graph of Figure 5 The lcm x lcm device weighed 1.26g and was used with a 108g battery power source, providing a light-weight ambulatory device. The power source consists of 4 conventional AA batteries and the simple current regulating circuit of Figure 6. The 108g power source also provides suitable power output for a 2cm x 2cm device. A 200g battery pack can power a Scm x Scm device.
The device could be used for skin and internal disorders. A range of pre-malignant, malignant and inflammatory diseases would be the target. Examples of pre-malignant skin disease are Bowen's disease, solar keratosis, arsenical keratosis, Paget's disease and radiodermatitis. Malignant diseases include all types of basal cell carcinomas, squamous cell carcinomas, secondary metastases, cutaneous T-cell lymphomas.
Inflammatory skin diseases include all types of dermatitis and psoriasis.
Further diseases that are potential targets are a range of pre-malignant, malignant and non-cutaneous disorders such as primary and metastatic tumours, as well as inflammatory disorders, eg connective tissue disease, all types of arthritis, inflammatory bowel disease.
Photopharmaceuticals can undergo reversible light-induced change, especially at high irradiances, which reduces the effectiveness of subsequent treatment - an effect referred to as photobleaching.
As reversible photobleaching of the photopharmaceutical is known to result in reduced penetration of light into the target tissue, a modified version of this device has a facility automatically to switch on and off the irradiation so delivering the desired dose, limiting photobleaching and enabling fresh uptake/metabolism of the photopharmaceutical within remaining viable target cells. This would have the clear benefit of increasing therapeutic effectiveness. The pulse trains constituting the light-output of such pulsed devices (periods 20, 200, 2000ms) are shown in Figure 7. Pulsed operation with a period of 20s, 200s and 2000s was also demonstrated and longer periods can be envisaged. Pulse shape and duration can readily be optimised for a particular application by experiment and calculation. In the examples shown, each period is constituted be a pulse and an interval between it and the next pulse, the interval being the same as the duration of the pulse.
The light-emitting device would be used either on its own as a simple light source applied to the skin or via an internal appliance such as a nasogastric tube, chest drain or stmt. For skin lesion management, the device would be used either alone or in combination with the photopharmaceutical in a translucent base such as a gel or ointment applied as a single dressing. Creams which scatter light may be used if they are sufficiently absorbed into the skin. A range of photopharmaceutical agents are currently available and it is expected that new agents of greater specificity and phototoxic effect will emerge. Examples of topical agents presently used include 5-aminolevulinic acid hydrochloride (Crawford Pharmaceuticals), methylaminolevulinc acid (Metfix, Photocure). Injectable drugs used in the main for internal malignancies, are two in number, Photofrin (Axcan) and Foscan (Biolitech).
A second example of the invention consists of a flexible device. Here the substrate consists of a polyester film in place of glass layer 11. Layers 12 to 16 are as for the first example. Epoxy layer 17 is very thin, and layer 18 is polyester. The inferior barrier properties of the plastic layers 11 and 18 mean that this device must be stored (or packaged) in an inert atmosphere such as dry nitrogen, but can be operated in air.
In this example, the element 10 is able to flex to fit the shape of a part of the patient's body, such as the arm. In this example, the transparent support layer and upper support layer are made from a thin flexible glass, a plastic/glass laminate or indium tin (ITO) coated polyester. The latter would be stored in an inert atmosphere until it is used.
Further alterations and amendments can be made by one skilled in the art within the scope of the invention herein disclosed. For example, the invention could be used, with a photopharmaceutical, in a cosmetic treatment, and/or have veterinary, as well as medical, applications.
Claims (15)
1. An ambulatory device for use in a therapeutic and/or cosmetic treatment, the device comprising an extensive organic light-emitting semiconductor which, in use, covers an area to be treated and emits electromagnetic radiation to cause said treatment of the area.
2. An ambulatory device according to claim 1 in which the light-emitting semiconductor has a surface area in the range 1 cm2 to 400 cm2.
3. An ambulatory device according to claim 2 in which the light-emitting semiconductor has a surface area in the range 3 cm2 to 100 cm2.
4. An ambulatory device according to any one preceding claim for use in the treatment of a human or animal patient by photodynamic therapy.
5. An ambulatory device according to any one preceding claim which is adapted to conform to the surface of the area to be exposed to light from the organic light-emitting semiconductor.
6. An ambulatory device according to any one preceding claim which is flexible so as to be capable of being formed into any of a number of possible different configurations in advance or extemporaneously to the shape of the body part to which it is to be applied.
7. An ambulatory device according to any one preceding claim which includes a transparent or translucent substrate layer.
8. An ambulatory device according to any one preceding claim which includes an adhesive surface for attaching the device to a patient.
9. An ambulatory device according to any one preceding claim wherein the organic light-emitting semiconductor is an organic light-emitting diode.
10. An ambulatory device according to any one preceding claim wherein the light output from the organic light-emitting semiconductor is pulsed.
11. An ambulatory device according to claim 10 wherein the light output is pulsed with a period of at least 20ms, at least 200ms, at least 2s, at least 20s, at least 200s or at least 2000s.
12.An ambulatory device according to any one preceding claim further comprising a photopharmaceutical preparation.
13. An ambulatory device as claimed in claim 12 wherein the photopharmaceutical preparation comprises an inactive compound which is metabolised in vivo to an active compound.
14. An ambulatory device substantially as described herein and illustrated in figures 1 and 2.
15. A.n ambulatory device for use in photodynamic therapy, the device comprising an electromagnetic radiation source, attachment means for attaching the electromagnetic radiation source to a patient and control means for activating and deactivating the source to cause the latter to emit a succession of light pulses for activating a photodynamic chemical, whilst reducing the effects of photobleaching on the chemical.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0127581.7 | 2001-11-17 | ||
| GBGB0127581.7A GB0127581D0 (en) | 2001-11-17 | 2001-11-17 | Therapeutic Light-emitting device |
| PCT/GB2002/005145 WO2003043697A2 (en) | 2001-11-17 | 2002-11-15 | Therapeutic light-emitting device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2464316A1 true CA2464316A1 (en) | 2003-05-30 |
| CA2464316C CA2464316C (en) | 2013-01-29 |
Family
ID=9925939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2464316A Expired - Fee Related CA2464316C (en) | 2001-11-17 | 2002-11-15 | Therapeutic light-emitting device |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7824435B2 (en) |
| EP (2) | EP1782857A3 (en) |
| JP (1) | JP4651281B2 (en) |
| KR (1) | KR100846274B1 (en) |
| CN (1) | CN100525858C (en) |
| AT (1) | ATE411834T1 (en) |
| AU (1) | AU2002343022B2 (en) |
| CA (1) | CA2464316C (en) |
| DE (1) | DE60229546D1 (en) |
| DK (1) | DK1444008T3 (en) |
| ES (1) | ES2316629T3 (en) |
| GB (3) | GB0127581D0 (en) |
| NZ (2) | NZ549901A (en) |
| WO (1) | WO2003043697A2 (en) |
| ZA (1) | ZA200403692B (en) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0127581D0 (en) * | 2001-11-17 | 2002-01-09 | Univ St Andrews | Therapeutic Light-emitting device |
| EP1556061B1 (en) * | 2002-10-04 | 2007-04-18 | Photokinetix Inc | Photokinetic delivery of biologically active substances using pulsed incoherent light |
| ES2570985T3 (en) * | 2003-02-25 | 2016-05-23 | Tria Beauty Inc | Apparatus and procedure for inhibiting new hair growth, safe for the eye and autonomous |
| EP2604216B1 (en) | 2003-02-25 | 2018-08-22 | Tria Beauty, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
| GB2408209A (en) * | 2003-11-18 | 2005-05-25 | Qinetiq Ltd | Flexible medical light source |
| JP4247102B2 (en) * | 2003-12-12 | 2009-04-02 | 株式会社フューテック | Beauty Equipment |
| CA2584970A1 (en) * | 2004-08-13 | 2006-02-16 | Derma Laser Inc. | Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound |
| US7686839B2 (en) * | 2005-01-26 | 2010-03-30 | Lumitex, Inc. | Phototherapy treatment devices for applying area lighting to a wound |
| US20060173514A1 (en) * | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
| US20060234959A1 (en) * | 2005-04-14 | 2006-10-19 | Advanced Photodynamic Technologies, Inc. | Photodynamic therapy utilizing multiple duty cycle light modulation |
| US8232721B2 (en) * | 2005-09-08 | 2012-07-31 | Osram Opto Semiconductors Gmbh | Efficiency enhancement methods for OLED light source through index bridging |
| EP1818077A1 (en) * | 2006-02-03 | 2007-08-15 | WaveLight AG | Phototherapy device for treating the skin |
| WO2007106856A2 (en) * | 2006-03-14 | 2007-09-20 | Allux Medical, Inc. | Phototherapy device and method of providing phototherapy to a body surface |
| GB0608315D0 (en) * | 2006-04-27 | 2006-06-07 | Univ St Andrews | Light emitting device for use in therapeutic and/or cosmetic treatment |
| US8057464B2 (en) | 2006-05-03 | 2011-11-15 | Light Sciences Oncology, Inc. | Light transmission system for photoreactive therapy |
| BRPI0712338A8 (en) | 2006-06-07 | 2016-09-27 | Koninklijke Philips Electronics Nv | LIGHTING DEVICE AND METHOD FOR MANUFACTURING A LIGHTING DEVICE |
| EP1935452A1 (en) * | 2006-12-19 | 2008-06-25 | Koninklijke Philips Electronics N.V. | Electrochromic device and photodynamic treatment device comprising such an electrochromic device |
| US9687671B2 (en) | 2008-04-25 | 2017-06-27 | Channel Investments, Llc | Optical sensor and method for identifying the presence of skin and the pigmentation of skin |
| EP2307914A4 (en) | 2008-07-10 | 2014-03-19 | 3M Innovative Properties Co | Retroreflective articles and devices having viscoelastic lightguide |
| EP2313800A4 (en) | 2008-07-10 | 2014-03-19 | 3M Innovative Properties Co | Viscoelastic lightguide |
| KR101578251B1 (en) | 2008-07-10 | 2015-12-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Retroreflective articles and devices having viscoelastic lightguide |
| CN102171593A (en) | 2008-08-08 | 2011-08-31 | 3M创新有限公司 | Lightguide having a viscoelastic layer for managing light |
| EP2384228A4 (en) * | 2009-01-05 | 2012-06-13 | Plextronics Inc | Organic light emitting diode phototherapy lighting system |
| CN102802676B (en) | 2009-06-25 | 2017-02-08 | 3M创新有限公司 | Light-activated antimicrobial article and method of use |
| BRPI1012154A2 (en) | 2009-06-30 | 2015-09-22 | 3M Innovative Properties Co | Light activated microbicidal article and method of use. |
| US8525397B2 (en) * | 2009-09-11 | 2013-09-03 | Koninklijke Philips N.V. | OLED devices with protection cover |
| CN102870020B (en) | 2009-10-30 | 2016-08-10 | 3M创新有限公司 | There is the illuminator of remote power feeding photoconduction |
| US20120245658A1 (en) * | 2009-12-09 | 2012-09-27 | Merck Patent Gmbh | Therapeutic and Cosmetic Electroluminescent Compositions |
| CN102754003B (en) | 2010-02-10 | 2014-06-18 | 3M创新有限公司 | Illumination device having viscoelastic layer |
| KR101757016B1 (en) | 2010-03-11 | 2017-07-11 | 메르크 파텐트 게엠베하 | Radiative fibers |
| WO2011110277A1 (en) | 2010-03-11 | 2011-09-15 | Merck Patent Gmbh | Fibers in therapy and cosmetics |
| TW201143832A (en) * | 2010-06-09 | 2011-12-16 | Forward Electronics Co Ltd | Phototherapy patch |
| KR101720828B1 (en) | 2010-07-26 | 2017-03-28 | 메르크 파텐트 게엠베하 | Nanocrystals in devices |
| JP6351974B2 (en) | 2011-02-14 | 2018-07-04 | メルク パテント ゲーエムベーハー | Devices and methods for treatment of cells and cellular tissues |
| DE102011117364A1 (en) | 2011-10-29 | 2013-05-02 | Merck Patent Gmbh | Skin whitening in phototherapy |
| US9687669B2 (en) | 2011-11-09 | 2017-06-27 | John Stephan | Wearable light therapy apparatus |
| KR20140123555A (en) | 2012-01-30 | 2014-10-22 | 메르크 파텐트 게엠베하 | Nanocrystals on fibers |
| WO2014018103A1 (en) | 2012-07-26 | 2014-01-30 | Brezinski Donna J | Portable phototherapy device |
| CN104854723B (en) * | 2012-12-17 | 2018-06-12 | 默克专利有限公司 | Inorganic barrier layer |
| US9561357B2 (en) * | 2013-03-15 | 2017-02-07 | Sonovia Holdings Llc | Light and ultrasonic transducer device for skin therapy |
| GB201308039D0 (en) | 2013-05-03 | 2013-06-12 | Ambicare Health Ltd | Photodynamic therapy |
| GB201310143D0 (en) | 2013-06-07 | 2013-07-24 | Ambicare Health Ltd | Delivery Mechanism for Photodynamic Therapy |
| WO2015014427A1 (en) | 2013-07-29 | 2015-02-05 | Merck Patent Gmbh | Electro-optical device and the use thereof |
| DE102014106952A1 (en) | 2014-05-16 | 2015-11-19 | Osram Oled Gmbh | Optoelectronic component, method for producing an optoelectronic component |
| KR102293606B1 (en) | 2014-10-21 | 2021-08-24 | 삼성전자주식회사 | Organic photoelectric device, and image sensor and electronic device including the smae |
| JP6799860B2 (en) * | 2015-08-28 | 2020-12-16 | 合同会社プレアデステクノロジーズ | Biologically applicable light irradiation device, how to use bioapplied light irradiation device, encapsulant of bioapplied light irradiation device, method of manufacturing encapsulant of bioapplied light irradiation device, method of using encapsulant of bioapplied light irradiation device , Set, skin disease treatment device and beauty treatment device |
| EP3463569A4 (en) | 2016-05-26 | 2020-01-29 | San Diego State University Research Foundation | Photoeradication of microorganisms with pulsed purple or blue light |
| CA3031991A1 (en) | 2016-07-27 | 2018-02-01 | Z2020 Llc | Componentry and devices for light therapy delivery and methods related thereto |
| US20190083809A1 (en) | 2016-07-27 | 2019-03-21 | Z2020, Llc | Componentry and devices for light therapy delivery and methods related thereto |
| US11020605B2 (en) | 2018-05-29 | 2021-06-01 | Carewear Corp. | Method and system for irradiating tissue with pulsed blue and red light to reduce muscle fatigue, enhance wound healing and tissue repair, and reduce pain |
| WO2020084876A1 (en) | 2018-10-26 | 2020-04-30 | 株式会社日本触媒 | Organic electric field light-emitting sheet for use in light cosmetology or light therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3786093A (en) | 1992-04-30 | 1993-11-29 | American Cyanamid Company | High-power light-emitting diodes for photodynamic therapy |
| US6156028A (en) * | 1994-03-21 | 2000-12-05 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment of wounds |
| US5616140A (en) * | 1994-03-21 | 1997-04-01 | Prescott; Marvin | Method and apparatus for therapeutic laser treatment |
| US5698866A (en) | 1994-09-19 | 1997-12-16 | Pdt Systems, Inc. | Uniform illuminator for phototherapy |
| US5703436A (en) * | 1994-12-13 | 1997-12-30 | The Trustees Of Princeton University | Transparent contacts for organic devices |
| US6548956B2 (en) * | 1994-12-13 | 2003-04-15 | The Trustees Of Princeton University | Transparent contacts for organic devices |
| US6011563A (en) * | 1995-04-24 | 2000-01-04 | The University Of Toledo | Computer controlled photoirradiation during photodynamic therapy |
| WO1998004184A2 (en) * | 1996-07-25 | 1998-02-05 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
| AU4048897A (en) * | 1996-08-12 | 1998-03-06 | Trustees Of Princeton University, The | Non-polymeric flexible organic light emitting device |
| US5827186A (en) * | 1997-04-11 | 1998-10-27 | Light Sciences Limited Partnership | Method and PDT probe for minimizing CT and MRI image artifacts |
| IT1293885B1 (en) * | 1997-04-16 | 1999-03-11 | Olivetti Canon Ind Spa | DEVICE AND METHOD FOR CHECKING THE ENERGY SUPPLIED TO AN EMISSION RESISTOR OF AN INK-JET THERMAL PRINT HEAD AND |
| US5957960A (en) * | 1997-05-05 | 1999-09-28 | Light Sciences Limited Partnership | Internal two photon excitation device for delivery of PDT to diffuse abnormal cells |
| RU2145247C1 (en) * | 1998-04-10 | 2000-02-10 | Жаров Владимир Павлович | Photomatrix therapeutic device for treatment of extended pathologies |
| US6096066A (en) * | 1998-09-11 | 2000-08-01 | Light Sciences Limited Partnership | Conformal patch for administering light therapy to subcutaneous tumors |
| US6936044B2 (en) * | 1998-11-30 | 2005-08-30 | Light Bioscience, Llc | Method and apparatus for the stimulation of hair growth |
| US6676655B2 (en) * | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
| JP2002534218A (en) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | Non-invasive vascular therapy |
| US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
| TWI273722B (en) * | 2000-01-27 | 2007-02-11 | Gen Electric | Organic light emitting device and method for mounting |
| US6700322B1 (en) * | 2000-01-27 | 2004-03-02 | General Electric Company | Light source with organic layer and photoluminescent layer |
| GB2370992B (en) | 2000-03-23 | 2002-11-20 | Photo Therapeutics Ltd | Therapeutic light source and method |
| US6764501B2 (en) * | 2001-04-10 | 2004-07-20 | Robert A. Ganz | Apparatus and method for treating atherosclerotic vascular disease through light sterilization |
| GB0127581D0 (en) * | 2001-11-17 | 2002-01-09 | Univ St Andrews | Therapeutic Light-emitting device |
| WO2004052238A2 (en) * | 2002-12-10 | 2004-06-24 | University Of Florida | Phototherapy bandage |
| US20050085455A1 (en) * | 2003-10-16 | 2005-04-21 | Light Sciences Corporation | Photodynamic therapy for local adipocyte reduction |
| US20060173514A1 (en) * | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
| US9854975B2 (en) * | 2006-06-12 | 2018-01-02 | Koninklijke Philips N.V. | Skin monitoring device, method of monitoring the skin, monitoring device, method of irradiating the skin, and use of an OLED |
| EP2384228A4 (en) * | 2009-01-05 | 2012-06-13 | Plextronics Inc | Organic light emitting diode phototherapy lighting system |
| US20130103123A1 (en) * | 2011-10-14 | 2013-04-25 | Sazzadur Rahman Khan | Light-Emitting Devices for Wound Healing |
-
2001
- 2001-11-17 GB GBGB0127581.7A patent/GB0127581D0/en not_active Ceased
-
2002
- 2002-11-15 AT AT02779682T patent/ATE411834T1/en active
- 2002-11-15 ES ES02779682T patent/ES2316629T3/en not_active Expired - Lifetime
- 2002-11-15 KR KR1020047007516A patent/KR100846274B1/en not_active IP Right Cessation
- 2002-11-15 GB GB0330067A patent/GB2393912B/en not_active Expired - Fee Related
- 2002-11-15 GB GB0226744A patent/GB2382991B/en not_active Expired - Fee Related
- 2002-11-15 NZ NZ549901A patent/NZ549901A/en not_active IP Right Cessation
- 2002-11-15 US US10/494,695 patent/US7824435B2/en not_active Expired - Fee Related
- 2002-11-15 AU AU2002343022A patent/AU2002343022B2/en not_active Ceased
- 2002-11-15 CA CA2464316A patent/CA2464316C/en not_active Expired - Fee Related
- 2002-11-15 EP EP07002898A patent/EP1782857A3/en not_active Withdrawn
- 2002-11-15 DE DE60229546T patent/DE60229546D1/en not_active Expired - Lifetime
- 2002-11-15 NZ NZ532832A patent/NZ532832A/en not_active IP Right Cessation
- 2002-11-15 EP EP02779682A patent/EP1444008B1/en not_active Expired - Lifetime
- 2002-11-15 DK DK02779682T patent/DK1444008T3/en active
- 2002-11-15 CN CNB028226321A patent/CN100525858C/en not_active Expired - Fee Related
- 2002-11-15 JP JP2003545372A patent/JP4651281B2/en not_active Expired - Fee Related
- 2002-11-15 WO PCT/GB2002/005145 patent/WO2003043697A2/en active IP Right Grant
-
2004
- 2004-05-13 ZA ZA200403692A patent/ZA200403692B/en unknown
-
2010
- 2010-10-08 US US12/900,534 patent/US9067061B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2464316C (en) | Therapeutic light-emitting device | |
| AU2007245407B2 (en) | Light emitting device for use in therapeutic and/or cosmetic treatment | |
| JP5882318B2 (en) | Nanocrystals in devices | |
| WO2012110178A1 (en) | Device and method for treatment of cells and cell tissue | |
| US20120283623A1 (en) | Phototherapy patch | |
| JP2017006347A (en) | Optical treatment apparatus | |
| JP2017006348A (en) | Optical treatment apparatus | |
| JP6799860B2 (en) | Biologically applicable light irradiation device, how to use bioapplied light irradiation device, encapsulant of bioapplied light irradiation device, method of manufacturing encapsulant of bioapplied light irradiation device, method of using encapsulant of bioapplied light irradiation device , Set, skin disease treatment device and beauty treatment device | |
| AU2007202975B2 (en) | Therapeutic light-emitting device | |
| JP2016221014A (en) | Optical treatment device | |
| Triana et al. | Quantum dot materials, devices, and their applications in photomedicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161115 |